Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data-Reference-Cited by-同舟云学术

Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data

Published:2016-02 Issue:2 Volume:17 Page:243-256
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Vale Claire L,Burdett Sarah,Rydzewska Larysa H M,Albiges Laurence,Clarke Noel W,Fisher David,Fizazi Karim,Gravis Gwenaelle,James Nicholas D,Mason Malcolm D,Parmar Mahesh K B,Sweeney Christopher J,Sydes Matthew R,Tombal Bertrand,Tierney Jayne F

Publisher

Elsevier BV

Subject

Oncology

Reference52 articles.

1. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11;Ferlay,2013

2. An update on androgen deprivation therapy for prostate cancer;Sharifi;Endocr Relat Cancer,2010

3. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial;Widmark;Lancet,2008

4. Final report of the Intergroup randomised study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation therapy alone in locally advanced prostate cancer;Mason;J Clin Oncol,2015

5. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study;Berthold;J Clin Oncol,2008

Cited by 360 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hormonal Agents in Localized and Advanced Prostate Cancer: Current Use and Future Perspectives;Clinical Genitourinary Cancer;2024-10

2. Computational Analysis of Treatment Resistant Cancer Cells;2024-08-31

3. Front-Line Therapeutic Strategy in Metastatic Hormone Sensitive Prostate Cancer: An Updated Therapeutic Algorithm;Clinical Genitourinary Cancer;2024-08

4. The Benefit of Combining Docetaxel with Androgen Deprivation Therapy in Localized and Metastatic Hormone-sensitive Prostate Cancer is Predicted by ERG Expression: An Analysis of Two GETUG Phase 3 Trials;European Urology Oncology;2024-07

5. Radiation Therapy for Locally Advanced Prostate Cancer: How Do We Treat Patients with cN1 Disease?;European Urology Focus;2024-07